BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16733218)

  • 41. Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition.
    Xu W; Soga S; Beebe K; Lee MJ; Kim YS; Trepel J; Neckers L
    Br J Cancer; 2007 Sep; 97(6):741-4. PubMed ID: 17712310
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.
    Krypuy M; Newnham GM; Thomas DM; Conron M; Dobrovic A
    BMC Cancer; 2006 Dec; 6():295. PubMed ID: 17184525
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma.
    Brachtel EF; Iafrate AJ; Mark EJ; Deshpande V
    Diagn Cytopathol; 2007 May; 35(5):257-62. PubMed ID: 17427221
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling.
    Conde E; Angulo B; Tang M; Morente M; Torres-Lanzas J; Lopez-Encuentra A; Lopez-Rios F; Sanchez-Cespedes M
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):710-7. PubMed ID: 16467080
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients.
    Reinmuth N; Jauch A; Xu EC; Muley T; Granzow M; Hoffmann H; Dienemann H; Herpel E; Schnabel PA; Herth FJ; Gottschling S; Lahm H; Steins M; Thomas M; Meister M
    Lung Cancer; 2008 Nov; 62(2):193-201. PubMed ID: 18450321
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
    Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
    Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of FISH, PCR, and immunohistochemistry in assessing EGFR status in lung adenocarcinoma and correlation with clinicopathologic features.
    El-Zammar OA; Zhang S; Katzenstein AL
    Diagn Mol Pathol; 2009 Sep; 18(3):133-7. PubMed ID: 19704257
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
    Willmore-Payne C; Holden JA; Layfield LJ
    Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EGFR inhibitors: what have we learned from the treatment of lung cancer?
    Giaccone G; Rodriguez JA
    Nat Clin Pract Oncol; 2005 Nov; 2(11):554-61. PubMed ID: 16270096
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway.
    Rosell R; Taron M; Reguart N; Isla D; Moran T
    Clin Cancer Res; 2006 Dec; 12(24):7222-31. PubMed ID: 17189393
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.
    Suda K; Tomizawa K; Mitsudomi T
    Cancer Metastasis Rev; 2010 Mar; 29(1):49-60. PubMed ID: 20108024
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer.
    Cadranel J; Zalcman G; Sequist L
    Eur Respir J; 2011 Jan; 37(1):183-93. PubMed ID: 21030453
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of HER2/neu in tumor progression and therapy.
    Ménard S; Casalini P; Campiglio M; Pupa SM; Tagliabue E
    Cell Mol Life Sci; 2004 Dec; 61(23):2965-78. PubMed ID: 15583858
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.